Enhanced hippocampal long-term potentiation following repeated MDMA treatment in Dark-Agouti rats

European Neuropsychopharmacology

Volumn 21, Issue 1, 2011, Pages 80-91

  Morini, Raffaella ^a   Mlinar, Boris ^a   Baccini, Gilda ^a   Corradetti, Renato ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Dark Agouti rats; Hippocampus; Long term potentiation; LTP; MDMA; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DARK AGOUTI RAT; HIPPOCAMPUS; LONG TERM POTENTIATION; MALE; NERVE CELL PLASTICITY; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE;

ANIMALS; EVOKED POTENTIALS; HALLUCINOGENS; HIPPOCAMPUS; LEARNING; LONG-TERM POTENTIATION; MALE; MEMORY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NOREPINEPHRINE; RATS; SEROTONIN; TIME FACTORS;

EID: 78650634168     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.07.007     Document Type: Article

References (61)

1. Able J.A., Gudelsky G.A., Vorhees C.V., Williams M.T. 3, 4-Methylenedioxymethamphetamine in adult rats produces deficits in path integration and spatial reference memory. Biol. Psychiatry 2006, 59:1219-1226.
2. Adams W., Kusljic S., van den Buuse B.M. Serotonin depletion in the dorsal and ventral hippocampus: effects on locomotor hyperactivity, prepulse inhibition and learning and memory. Neuropharmacology 2008, 55:1048-1055.
3. Altman H.J., Normile H.J., Galloway M.P., Ramirez A., Azmitia E.C. Enhanced spatial discrimination learning in rats following 5, 7-DHT-induced serotonergic deafferentation of the hippocampus. Brain Res. 1990, 518:61-66.
4. Anderson W.W., Collingridge G.L. The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J. Neurosci. Meth. 2001, 108:71-83.
5. Arias-Cavieres A., Rozas C., Reyes-Parada M., Barrera N., Pancetti F., Loyola S., Lorca R.A., Zeise M.L., Morales B. MDMA ("ecstasy") impairs learning in the Morris Water Maze and reduces hippocampal LTP in young rats. Neurosci. Lett. 2010, 469:375-379.
6. Baccini, G., Morini, R., Corradetti, R. and Mlinar, B., 2009. Repeated (±)3, 4-methylenedioxymethamphetamine treatment enhances hippocampal long-term potentiation in Dark-Agouti rats. 22nd ECNP Congress, 12-16 September 2009 Istanbul, Turkey. Abstract P.6.d.010.
7. Bannerman D.M., Rawlins J.N., McHugh S.B., Deacon R.M., Yee B.K., Bast T., Zhang W.N., Pothuizen H.H., Feldon J. Regional dissociations within the hippocampus - memory and anxiety. Neurosci. Biobehav. Rev. 2004, 28:273-283.
8. Barrionuevo G., Brown T.H. Associative long-term potentiation in hippocampal slices. Proc. Natl. Acad. Sci. U S A 1983, 80:7347-7351.
9. Barrionuevo G., Schottler F., Lynch G. The effects of repetitive low frequency stimulation on control and "potentiated" synaptic responses in the hippocampus. Life Sci. 1980, 27:2385-2391.
10. Battaglia G., Yeh S.Y., De Souza E.B. MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 1988, 29:269-274.
11. Battaglia G., Yeh S.Y., O'Hearn E., Molliver M.E., Kuhar M.J., De Souza E.B. 3, 4-Methylenedioxymethamphetamine and 3, 4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. J. Pharmacol. Exp. Ther. 1987, 242:911-916.
12. Baumann M.H., Wang X., Rothman R.B. 3, 4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 2007, 189:407-424.
13. Bliss T.V., Lømo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J. Physiol. 1973, 232:331-356.
14. Broening H.W., Bacon L., Slikker W. Age modulates the long-term but not the acute effects of the serotonergic neurotoxicant 3, 4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 1994, 271:285-293.
15. Buchert R., Thomasius R., Nebeling B., Petersen K., Obrocki J., Jenicke L., Wilke F., Wartberg L., Zapletalova P., Clausen M. Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. J. Nucl. Med. 2003, 44:375-384.
16. Capela J.P., Carmo H., Remiao F., Bastos M.L., Meisel A., Carvalho F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol. Neurobiol. 2009, 39:210-271.
17. Colado M.I., Williams J.L., Green A.R. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3, 4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol. 1995, 115:1281-1289.
18. Fantegrossi W.E., Godlewski T., Karabenick R.L., Stephens J.M., Ullrich T., Rice K.C., Woods J.H. Pharmacological characterization of the effects of 3, 4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) 2003, 166:202-211.
19. Fischer C., Hatzidimitriou G., Wlos J., Katz J., Ricaurte G. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/±)3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J. Neurosci. 1995, 15:5476-5485.
20. Gong N., Li Y., Cai G.Q., Niu R.F., Fang Q., Wu K., Chen Z., Lin L.N., Xu L., Fei J., Xu T.L. GABA transporter-1 activity modulates hippocampal theta oscillation and theta burst stimulation-induced long-term potentiation. J. Neurosci. 2009, 29:15836-15845.
21. Gouzoulis-Mayfrank E., Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?. Addiction 2006, 101:348-361.
22. Gouzoulis-Mayfrank E., Thimm B., Rezk M., Hensen G., Daumann J. Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:819-827.
23. Gray J.A., McNaughton N. The neuropsychology of anxiety 2000, Oxford University Press, Oxford. 2nd ed.
24. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 2003, 55:463-508.
25. Hatzidimitriou G., McCann U.D., Ricaurte G.A. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/±)3, 4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J. Neurosci. 1999, 19:5096-5107.
26. Hill A.J. First occurrence of hippocampal spatial firing in a new environment. Exp. Neurol. 1978, 62:282-297.
27. Jacobsen L.K., Mencl W.E., Pugh K.R., Skudlarski P., Krystal J.H. Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology (Berl) 2004, 173:383-390.
28. Kovacs G.G., Ando R.D., Adori C., Kirilly E., Benedek A., Palkovits M., Bagdy G. Single dose of MDMA causes extensive decrement of serotoninergic fibre density without blockage of the fast axonal transport in Dark Agouti rat brain and spinal cord. Neuropathol. Appl. Neurobiol. 2007, 33:193-203.
29. Larson J., Lynch G. Induction of synaptic potentiation in hippocampus by patterned stimulation involves two events. Science 1986, 232:985-988.
30. Larson J., Wong D., Lynch G. Patterned stimulation at the theta frequency is optimal for the induction of hippocampal long-term potentiation. Brain Res. 1986, 368:347-350.
31. Lehmann O., Bertrand F., Jeltsch H., Morer M., Lazarus C., Will B., Cassel J.C. 5, 7-DHT-induced hippocampal 5-HT depletion attenuates behavioural deficits produced by 192 IgG-saporin lesions of septal cholinergic neurons in the rat. Eur. J. Neurosci. 2002, 15:1991-2006.
32. Lew R., Sabol K.E., Chou C., Vosmer G.L., Richards J., Seiden L.S. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies. J Pharmacol. Exp. Ther. 1996, 276:855-865.
33. Li S., Cullen W.K., Anwyl R., Rowan M.J. Dopamine-dependent facilitation of LTP induction in hippocampal CA1 by exposure to spatial novelty. Nat. Neurosci. 2003, 6:526-531.
34. Majlessi N., Kadkhodaee M., Parviz M., Naghdi N. Serotonin depletion in rat hippocampus attenuates L-NAME-induced spatial learning deficits. Brain Res. 2003, 963:244-251.
35. Markstein R., Matsumoto M., Kohler C., Togashi H., Yoshioka M., Hoyer D. Pharmacological characterisation of 5-HT receptors positively coupled to adenylyl cyclase in the rat hippocampus. Naunyn Schmiedebergs Arch. Pharmacol. 1999, 359:454-459.
36. 11C]DASB. Neuropsychopharmacology 2005, 30:1741-1750.
37. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 1998, 352:1433-1437.
38. 4 receptor activation induces long-lasting EPSP-spike potentiation in CA1 pyramidal neurons. Eur. J. Neurosci. 2006, 24:719-731.
39. 1 receptors. Neuropsychopharmacology 2008, 33:1464-1475.
40. Morgan M.J. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 2000, 152:230-248.
41. Morris R.G., Garrud P., Rawlins J.N., O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 1982, 297:681-683.
42. Moser M.B., Moser E.I., Forrest E., Andersen P., Morris R.G. Spatial learning with a minislab in the dorsal hippocampus. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:9697-9701.
43. Moyano S., Del Río J., Frechilla D. Acute and chronic effects of MDMA on molecular mechanisms implicated in memory formation in rat hippocampus: surface expression of CaMKII and NMDA receptor subunits. Pharmacol. Biochem. Behav. 2005, 82:190-199.
44. O'Hearn E., Battaglia G., De Souza E.B., Kuhar M.J., Molliver M.E. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J. Neurosci. 1988, 8:2788-2803.
45. O'Shea E., Granados R., Esteban B., Colado M.I., Green A.R. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 1998, 37:919-926.
46. Otto T., Eichenbaum H., Wiener S.I., Wible C.G. Learning-related patterns of CA1 spike trains parallel stimulation parameters optimal for inducing hippocampal long-term potentiation. Hippocampus 1991, 1:181-192.
47. Pastalkova E., Serrano P., Pinkhasova D., Wallace E., Fenton A.A., Sacktor T.C. Storage of spatial information by the maintenance mechanism of LTP. Science 2006, 313:1141-1144.
48. Ranck J.B. Studies on single neurons in dorsal hippocampal formation and septum in unrestrained rats. I. Behavioral correlates and firing repertoires. Exp. Neurol. 1973, 41:461-531.
49. Reneman L., Booij J., De Bruin K., Reitsma J.B., de Wolff F.A., Gunning W.B., den Heeten G.J., van den Brink W. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001, 358:1864-1869.
50. Ressler K.J., Nemeroff C.B. Role of serotonergic and noradrenergic systems in the patophysiology of depression and anxiety disorders. Depression ans Anxiety 12. Supplement 2000, 1:2-19.
51. Rex A., Voigt J.P., Fink H. Anxiety but not arousal increases 5-hydroxytryptamine release in the rat ventral hippocampus in vivo. Eur. J. Neurosci. 2005, 22:1185-1189.
52. Ricaurte G.A., Forno L.S., Wilson M.A., DeLanney L.E., Irwin I., Molliver M.E., Langston J.W. (+/±)3, 4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 1988, 260:51-55.
53. Schmidt C.J., Wu L., Lovenberg W. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur. J. Pharmacol. 1986, 124:175-178.
54. Semple D.M., Ebmeier K.P., Glabus M.F., O'Carroll R.E., Johnstone E.C. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br. J. Psychiatry 1999, 175:63-69.
55. Sharkey J., McBean D.E., Kelly P.A. Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy"). Psychopharmacology (Berl) 1991, 105:113-118.
56. Simantov R., Peng W. MDMA (Ecstasy) controls in concert a group of genes involved in GABA neurotransmission. FEBS Lett. 2004, 563:3-6.
57. Sprague J.E., Preston A.S., Leifheit M., Woodside B. Hippocampal serotonergic damage induced by MDMA (ecstasy): effects on spatial learning. Physiol. Behav. 2003, 79:281-287.
58. Staubli U., Lynch G. Stable depression of potentiated synaptic responses in the hippocampus with 1-5Hz stimulation. Brain Res. 1990, 513:113-118.
59. Thomas M.J., Moody T.D., Makhinson M., O'Dell T.J. Activity-dependent [beta]-adrenergic modulation of low frequency stimulation induced LTP in the hippocampal CA1 region. Neuron 1996, 17:475-482.
60. Wagner J.J., Alger B.E. Homosynaptic LTD and depotentiation: do they differ in name only?. Hippocampus 1996, 6:24-29.
61. Whitlock J.R., Heynen A.J., Shuler M.G., Bear M.F. Learning induces long-term potentiation in the hippocampus. Science 2006, 313:1093-1097.